397 related articles for article (PubMed ID: 23804073)
1. Modulation of TSC-mTOR signaling on immune cells in immunity and autoimmunity.
Yang H; Wang X; Zhang Y; Liu H; Liao J; Shao K; Chu Y; Liu G
J Cell Physiol; 2014 Jan; 229(1):17-26. PubMed ID: 23804073
[TBL] [Abstract][Full Text] [Related]
2. Role of TSC-mTOR pathway in diabetic nephropathy.
Inoki K
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S59-62. PubMed ID: 18926585
[TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
5. Tsc1 deficiency-mediated mTOR hyperactivation in vascular endothelial cells causes angiogenesis defects and embryonic lethality.
Ma A; Wang L; Gao Y; Chang Z; Peng H; Zeng N; Gui YS; Tian X; Li X; Cai B; Zhang H; Xu KF
Hum Mol Genet; 2014 Feb; 23(3):693-705. PubMed ID: 24129405
[TBL] [Abstract][Full Text] [Related]
6. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
[TBL] [Abstract][Full Text] [Related]
7. Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation andloss of marginal zone B cells.
Benhamron S; Tirosh B
Eur J Immunol; 2011 Aug; 41(8):2390-6. PubMed ID: 21674478
[TBL] [Abstract][Full Text] [Related]
8. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
[TBL] [Abstract][Full Text] [Related]
9. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Kwiatkowski DJ; Manning BD
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
[TBL] [Abstract][Full Text] [Related]
10. Mammalian target of rapamycin signaling in the podocyte.
Inoki K; Huber TB
Curr Opin Nephrol Hypertens; 2012 May; 21(3):251-7. PubMed ID: 22388550
[TBL] [Abstract][Full Text] [Related]
11. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions.
Matthew EM; Hart LS; Astrinidis A; Navaraj A; Dolloff NG; Dicker DT; Henske EP; El-Deiry WS
Cell Cycle; 2009 Dec; 8(24):4168-75. PubMed ID: 20054236
[TBL] [Abstract][Full Text] [Related]
12. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation.
Uhlmann EJ; Li W; Scheidenhelm DK; Gau CL; Tamanoi F; Gutmann DH
Glia; 2004 Aug; 47(2):180-8. PubMed ID: 15185396
[TBL] [Abstract][Full Text] [Related]
13. Tuberous sclerosis complex 1-mechanistic target of rapamycin complex 1 signaling determines brown-to-white adipocyte phenotypic switch.
Xiang X; Lan H; Tang H; Yuan F; Xu Y; Zhao J; Li Y; Zhang W
Diabetes; 2015 Feb; 64(2):519-28. PubMed ID: 25213336
[TBL] [Abstract][Full Text] [Related]
14. PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.
Alves MM; Fuhler GM; Queiroz KC; Scholma J; Goorden S; Anink J; Spek CA; Hoogeveen-Westerveld M; Bruno MJ; Nellist M; Elgersma Y; Aronica E; Peppelenbosch MP
Sci Rep; 2015 Sep; 5():14534. PubMed ID: 26412398
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.
Ma L; Chen Z; Erdjument-Bromage H; Tempst P; Pandolfi PP
Cell; 2005 Apr; 121(2):179-93. PubMed ID: 15851026
[TBL] [Abstract][Full Text] [Related]
16. mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis.
Dello Russo C; Lisi L; Feinstein DL; Navarra P
Glia; 2013 Mar; 61(3):301-11. PubMed ID: 23044764
[TBL] [Abstract][Full Text] [Related]
17. mTOR signaling in T cell immunity and autoimmunity.
Liu Y; Zhang DT; Liu XG
Int Rev Immunol; 2015 Jan; 34(1):50-66. PubMed ID: 25019278
[TBL] [Abstract][Full Text] [Related]
18. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
19. The TSC1-mTOR-PLK axis regulates the homeostatic switch from Schwann cell proliferation to myelination in a stage-specific manner.
Jiang M; Rao R; Wang J; Wang J; Xu L; Wu LM; Chan JR; Wang H; Lu QR
Glia; 2018 Sep; 66(9):1947-1959. PubMed ID: 29722913
[TBL] [Abstract][Full Text] [Related]
20. Leukemia inhibitory factor (LIF) withdrawal activates mTOR signaling pathway in mouse embryonic stem cells through the MEK/ERK/TSC2 pathway.
Cherepkova MY; Sineva GS; Pospelov VA
Cell Death Dis; 2016 Jan; 7(1):e2050. PubMed ID: 26775702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
